Grup de Recerca: Neurociència de la conductual traslacional

Responsable: Dra. Lydia Giménez-Llort

Seu: Unitat de Psicologia Mèdica, Departament de Psiquiatria i Medicina Legal Facultat de Medicina Campus de Bellaterra, s/n 08193 Bellaterra (Cerdanyola del Vallès)

Tel. 935812378 Fax. 935811435

email: Lidia.Gimenez@uab.es

Components: Lydia Giménez-Llort, Toni Cañete, Mikel Santana, Lidia Castillo, Aida Muntsant, Danny Marín, José Prieto, Antonia Ferrer, Mara Cristina Mangas, Clara Pérez i David Sánchez

Línies de recerca:

1. Dolor, BPSD i cognició en l'envelliment i el dany cognitiu, especialment a les demències
2. Estimulació sensorial, exercici, enriquiment cognitiu i social com a estratègies preventives i terapèutiques
3. Farmacologia conductual de les interaccions NMDA-DA-Adenosina en models animals per trastorns neurològics i psiquiàtrics

Projectes actuals i recents:

TÍTOL DEL PROJECTE: 3-O- sulfated heparan sulfate translocation in altered membrane biology: A new strategy for early population screening and halting Alzheimer's neurodegeneration
ENTITAT FINANCIADORA: H2020-EU.1.2.1.-FET Open (2017-2020)
DURACIÓN DES DE-FINS A: 2017/20
COORDINACIO: Dulce Papy, UPEC, France
INVESTIGADOR/A PRINCIPAL UAB: Lydia Giménez-Llort

TÍTOL DEL PROJECTE: Pain Assessment in Patients with Impaired Cognition, especially Dementia. COST-action TD-1005 (2010-2015).
ENTITAT FINANCIADORA COST- Action, EU
COORDINACIO: Stefan Lautenbacher, Alemanya
INVESTIGADOR/A PRINCIPAL UAB: Lydia Giménez-Llort

TÍTOL DEL PROJECTE: Mortality risk in Alzheimer's disease associated to treatment with antipsychotics, risk factors and preventive/therapeutical strategies: Studies in triple-transgenic 3xTgAD mice for Alzheimer's disease.
ENTITAT FINANCIADORA::ISCIII PI10/00283
PARTICIPANTS: Institut de Neurociències, UAB (Barcelona, España); UVAMID- Hospital Santa Katerina (Girona, España), Universidad de la Laguna (Tenerife, España); Molecular Medicine Center, Karolinska Hospital, Karolinska Institute (Estocolmo, Suecia)
DURACIÓN DES DE-FINS A: 2013/14 (prórroga de un año de P41).
INVESTIGADOR/A PRINCIPAL: Lydia Giménez-Llort

TÍTOL DEL PROJECTE: Modulación de la actividad de receptores inmunitarios como una nueva estratégia terapéutica para el daño agudo en el sistema nervioso central
ENTITAT FINANCIADORA:Fundació La Marató de TV3 / 2011- 110531
PARTICIPANTS: Institut de Neurociències, UAB (Barcelona, España); IIBB-CSIC (Barcelona, España), Facultat de Ciències de la Salut i de la Vida UPF (Barcelona, España); CIBBIM -

Nanomedicina Hospital Universitari Vall d'Hebron (Barcelona, España); Instituto Pasteur de Montevideo (Montevideo, Uruguay),
DURACIÓ DES DE-FINS A: 2012/14
COORDINACIO: Carme Solà Subirana
INVESTIGADOR/A PRINCIPAL UAB: Lydia Giménez-Llort

Publicacions recents seleccionades:

Crosstalk between Peripheral Small Vessel Properties and Anxious-like Profiles: Sex, Genotype, and Interaction Effects in Mice with Normal Aging and 3×Tg-AD mice at Advanced Stages of Disease.
Jiménez-Altayó F, Sánchez-Ventura J, Vila E, Giménez-Llort L.
J Alzheimers Dis. 2018;62(4):1531-1538. doi: 10.3233/JAD-171019.

Long-term Treatment with Low-Dose Caffeine Worsens BPSD-Like Profile in 3xTg-AD Mice Model of Alzheimer's Disease and Affects Mice with Normal Aging.
Baeta-Corral R, Johansson B, Giménez-Llort L.
Front Pharmacol. 2018 Feb 15;9:79. doi: 10.3389/fphar.2018.00079. eCollection 2018.

Sexual Dimorphism in the Behavioral Responses and the Immunoendocrine Status in d-Galactose-Induced Aging.
Baeta-Corral R, Castro-Fuentes R, Giménez-Llort L.
J Gerontol A Biol Sci Med Sci. 2018 Aug 10;73(9):1147-1157. doi: 10.1093/gerona/gly031.

Reducing the Levels of Akt Activation by PDK1 Knock-in Mutation Protects Neuronal Cultures against Synthetic Amyloid-Beta Peptides.
Yang S, Pascual-Guiral S, Ponce R, Giménez-Llort L, Baltrons MA, Arancio O, Palacio JR, Clos VM, Yuste VJ, Bayascas JR.
Front Aging Neurosci. 2018 Jan 8;9:435. doi: 10.3389/fnagi.2017.00435. eCollection 2017.

Secreted αKlotho isoform protects against age-dependent memory deficits.
Massó A, Sánchez A, Bosch A, Giménez-Llort L*, Chillón M*
Mol Psychiatry. 2018 Sep;23(9):1-11. doi: 10.1038/mp.2017.211. Epub 2017 Oct 31.

Survival Curves and Behavioral Profiles of Female 3xTg-AD Mice Surviving to 18-Months of Age as Compared to Mice with Normal Aging.
Torres-Lista V, De la Fuente M, Giménez-Llort L.
J Alzheimers Dis Rep. 2017 Jul 6;1(1):47-57. doi: 10.3233/ADR-170011.

Behavioural effects of novel multitarget anticholinesterasic derivatives in Alzheimer's disease.
Giménez-Llort L, Ratia M, Pérez B, Camps P, Muñoz-Torrero D, Badia A, Clos MV.
Behav Pharmacol. 2017 Apr;28(2 and 3-Spec Issue):124-131. doi: 10.1097/FBP.0000000000000292. Review.

Early postnatal handling and environmental enrichment improve the behavioral responses of 17-month-old 3xTg-AD and non-transgenic mice in the Forced Swim Test in a gender-dependent manner.
Torres-Lista V, Giménez-Llort L.
Behav Processes. 2015 Nov;120:120-7. doi: 10.1016/j.beproc.2015.09.011. Epub 2015 Sep 30.

Experimental pain processing in individuals with cognitive impairment: current state of the science.
Defrin R, Amanzio M, de Tommaso M, Dimova V, Filipovic S, Finn DP, **Gimenez-Llort L**, Invitto S, Jensen-Dahm C, Lautenbacher S, Oosterman JM, Petrini L, Pick CG, Pickering G, Vase L, Kunz M.
Pain. 2015 Aug;156(8):1396-408. doi: 10.1097/j.pain.0000000000000195. Review.

Crosstalk between behavior and immune system during the prodromal stages of Alzheimer's disease.
Giménez-Llort L*, Torres-Lista V, De la Fuente M.
Curr Pharm Des. 2014;20(29):4723-32. Review.

Differential modulation of TREM2 protein during postnatal brain development in mice.
Chertoff M, Shrivastava K, Gonzalez B, Acarin L, Giménez-Llort L.
PLoS One. 2013 Aug 19;8(8):e72083. doi: 10.1371/journal.pone.0072083. eCollection 2013.

Tail-flick test response in 3×Tg-AD mice at early and advanced stages of disease.
Baeta-Corral R, Defrin R, Pick CG, Giménez-Llort L.
Neurosci Lett. 2015 Jul 23;600:158-63. doi: 10.1016/j.neulet.2015.06.007. Epub 2015 Jun 16.

Marble-burying is enhanced in 3xTg-AD mice, can be reversed by risperidone and it is modulable by handling.
Torres-Lista V, López-Pousa S, Giménez-Llort L.
Behav Processes. 2015 Jul;116:69-74. doi: 10.1016/j.beproc.2015.05.001. Epub 2015 May 6.